BioSpace News Archive

Detailed primary results from the positive Phase II DESTINY-Lung01 trial of ENHERTU®, the AstraZeneca and Daiichi Sankyo Company, Limited HER2-directed antibody drug conjugate, showed a robust and durable tumor response in previously treated patients with HER2-mutant unresectable and/or metastatic non-squamous non-small cell lung cancer.

Exelixis, Inc. announced detailed results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer.

Merck announced the first results from the Phase 3 KEYNOTE-716 trial, in which adjuvant treatment with KEYTRUDA, Merck’s anti-PD-1 therapy, showed a statistically significant and clinically meaningful improvement in recurrence-free survival, the trial’s primary endpoint, compared to placebo in patients with resected high-risk stage II melanoma; KEYTRUDA is the first anti-PD-1 therapy to demonstrate this.

Updated results from the CASPIAN Phase III trial showed AstraZeneca’s IMFINZI® in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival benefit at three years for adults with extensive-stage small cell lung cancer treated in the 1st-line setting.

Ipsen announced presentation of new analyses at the European Society for Medical Oncology Congress 2021 across different forms of cancer for people treated with Cabometyx®.

Detailed primary results from the positive, pivotal DESTINY-Lung01 phase 2 trial of ENHERTU®, the Daiichi Sankyo Company, Limited and AstraZeneca HER2 directed antibody drug conjugate, showed a robust and durable tumor response in previously-treated patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer.

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology therapies, announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 clinical trial.

Merck announced the presentation of the full results from the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy with or without bevacizumab for the first-line treatment of persistent, recurrent or metastatic cervical cancer at the European Society for Medical Oncology Congress 2021.

Detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial showed that ENHERTU®, the AstraZeneca and Daiichi Sankyo Company, Limited HER2-directed antibody drug conjugate, demonstrated superior progression-free survival versus trastuzumab emtansine, a HER2-directed ADC currently approved to treat patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane.

Personalis, Inc., a leader in advanced genomics for population sequencing and cancer, announced that the U.S. Department of Veterans Affairs Million Veteran Program has issued a new task order under its current contract with the company, with a value of up to approximately $10 million.